isopropyl-[1-(4-phenyl-1H-imidazol-2-yl)-ethyl]-amine | 864825-25-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: isopropyl-[1-(4-phenyl-1H-imidazol-2-yl)-ethyl]-amine
• 英文别名: N-[(1S)-1-(5-phenyl-1H-imidazol-2-yl)ethyl]propan-2-amine
• CAS: 864825-25-2
• 化学式: C₁₄H₁₉N₃
• 分子量: 229.325
• InChiKey: VLEQILFMQCPXHH-NSHDSACASA-N

物化性质

• 沸点：
  421.8±28.0 °C(Predicted)
• 密度：
  1.049±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  40.7
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  isopropyl-[1-(4-phenyl-1H-imidazol-2-yl)-ethyl]-amine 在 盐酸 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 四氢呋喃 、 水 、 乙酸乙酯 、 N,N-二甲基甲酰胺 为溶剂， 生成
  参考文献：
  名称：

  Identification of a dual δ OR antagonist/μ OR agonist as a potential therapeutic for diarrhea-predominant Irritable Bowel Syndrome (IBS-d)

  摘要：

  A small set of acyclic analogs 5 were prepared to explore their structure-activity relationships (SARs) relative to heterocyclic core, opioid receptor (OR) agonists 4. Compound 5l was found to have very favorable OR binding affinities at the δ and μ ORs (r K(i) δ=1.3 nM; r K(i) μ=0.9 nM; h K(i) μ=1.7 nM), with less affinity for the κ OR (gp K(i) κ=55 nM). The OR functional profile for 5l varied from the previously described dual δ/μ OR agonists 4, with 5l being a potent, mixed dual δ OR antagonist/μ OR agonist [δ IC(50)=89 nM (HVD); μ EC(50)=1 nM (GPI); κ EC(50)=1.6 μM (GPC)]. Compound 5l has progressed through a clinical Phase II Proof of Concept study on 800 patients suffering from diarrhea-predominant Irritable Bowel Syndrome (IBS-d). This Phase II study was recently completed successfully, with 5l demonstrating statistically significant efficacy over placebo.

  DOI：

  10.1016/j.bmcl.2012.05.042
• 作为产物：
  描述：

  1-(4-苯基-1H-咪唑-2-Yl)乙基氨基甲酸苄酯 在 sodium tetrahydroborate 、 palladium 10% on activated carbon 、 氢气 作用下， 以 甲醇 为溶剂， 生成 isopropyl-[1-(4-phenyl-1H-imidazol-2-yl)-ethyl]-amine
  参考文献：
  名称：

  Identification of a dual δ OR antagonist/μ OR agonist as a potential therapeutic for diarrhea-predominant Irritable Bowel Syndrome (IBS-d)

  摘要：

  A small set of acyclic analogs 5 were prepared to explore their structure-activity relationships (SARs) relative to heterocyclic core, opioid receptor (OR) agonists 4. Compound 5l was found to have very favorable OR binding affinities at the δ and μ ORs (r K(i) δ=1.3 nM; r K(i) μ=0.9 nM; h K(i) μ=1.7 nM), with less affinity for the κ OR (gp K(i) κ=55 nM). The OR functional profile for 5l varied from the previously described dual δ/μ OR agonists 4, with 5l being a potent, mixed dual δ OR antagonist/μ OR agonist [δ IC(50)=89 nM (HVD); μ EC(50)=1 nM (GPI); κ EC(50)=1.6 μM (GPC)]. Compound 5l has progressed through a clinical Phase II Proof of Concept study on 800 patients suffering from diarrhea-predominant Irritable Bowel Syndrome (IBS-d). This Phase II study was recently completed successfully, with 5l demonstrating statistically significant efficacy over placebo.

  DOI：

  10.1016/j.bmcl.2012.05.042

文献信息

• Novel compounds as opioid receptor modulators
  申请人：Breslin J. Henry

  公开号：US20050203143A1

  公开（公告）日：2005-09-15

  The present invention is directed to novel opioid receptor modulators of Formula (I). The invention further relates to methods for preparing such compounds, pharmaceutical compositions containing them, and their use in the treatment of disorders that may be ameliorated or treated by the modulation of opioid receptors.

  本发明涉及式(I)的新型阿片受体调节剂。该发明进一步涉及制备这类化合物的方法、包含它们的药物组合物，以及它们在治疗可通过调节阿片受体得到改善或治疗的疾病中的用途。
• Process for the preparation of opioid modulators
  申请人：Cai Chaozhong

  公开号：US20060211861A1

  公开（公告）日：2006-09-21

  The present invention is directed to novel processes for the preparation of opioid modulators (agonists and antagonists) and intermediates in their synthesis. The opioid modulators are useful for the treatment and prevention of as pain and gastrointestinal disorders.

  本发明涉及用于制备阿片类药物调节剂（激动剂和拮抗剂）及其合成中间体的新工艺。这些阿片类药物调节剂可用于治疗和预防疼痛和胃肠道疾病。
• NOVEL COMPOUNDS AS OPIOID RECEPTOR MODULATORS
  申请人：Breslin J. Henry

  公开号：US20080096888A1

  公开（公告）日：2008-04-24

  The present invention is directed to novel opioid receptor modulators of Formula (I). The invention further relates to methods for preparing such compounds, pharmaceutical compositions containing them, and their use in the treatment of disorders that may be ameliorated or treated by the modulation of opioid receptors.

  本发明涉及式(I)的新型阿片受体调节剂。本发明还涉及制备这些化合物的方法、含有它们的药物组合物以及它们在治疗可能通过调节阿片受体改善或治疗的疾病中的应用。
• PROCESS FOR THE PREPARATION OF OPIOD MODULATORS
  申请人：Cai Chaozhong

  公开号：US20100036132A1

  公开（公告）日：2010-02-11

  The present invention is directed to novel processes for the preparation of opioid modulators (agonists and antagonists) and intermediates in their synthesis. The opioid modulators are useful for the treatment and prevention of as pain and gastrointestinal disorders.

  本发明涉及制备阿片类调节剂（激动剂和拮抗剂）及其合成中间体的新型工艺。这些阿片类调节剂可用于治疗和预防疼痛和胃肠道疾病。
• PROCESS FOR THE PREPARATION OF OPIOID MODULATORS
  申请人：Cai Chaozhong

  公开号：US20100152460A1

  公开（公告）日：2010-06-17

  The present invention is directed to novel processes for the preparation of opioid modulators (agonists and antagonists) and intermediates in their synthesis. The opioid modulators are useful for the treatment and prevention of as pain and gastrointestinal disorders.

  本发明涉及一种新型工艺，用于制备阿片类调节剂（激动剂和拮抗剂）及其合成中间体。这些阿片类调节剂可用于治疗和预防疼痛和胃肠障碍。